Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Artrya Limited (AYA) Share Price & Analysis

AYA Stock Chart & Stats

A$2.86A$0.09(3.25%)
At close: 4:10 PM GMT+11
AU$3AU$4AU$510 Aug24 Aug7 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
AUD 2.74 - AUD 2.87
52-Week Range
AUD 2.00 - AUD 6.49
Previous Close
AUD 2.77
Volume
N/A
Average Volume (3M)
1.45M
Market Cap
AUD 453.27M
Enterprise Value
AUD 920.15M
Total Cash (Recent Filing)
AUD 74.17M
Total Debt (Recent Filing)
AUD 247.00K
Price to Earnings (P/E)
―
Beta
2.96
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-0.08
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low debt reduces near-term solvency pressure and limits interest obligations, preserving more flexibility for product development and commercial investment. This balance-sheet cushion is a durable strength even though it does not offset the company’s current losses or cash consumption.

Focused Clinical Software

A focused clinical decision-support platform gives Artrya a clearly defined role in cardiovascular diagnosis and risk assessment. Embedding specialized analysis into hospital, imaging, and cardiology workflows could support recurring use if the software achieves sustained clinical adoption.

Recurring Revenue Model Potential

Licensing, subscription, and usage-based models can create repeatable revenue as healthcare providers process more studies or expand site adoption. If commercial execution improves, this structure could provide greater revenue visibility and scalability than one-time software sales.

Bears Say

Minimal Revenue And Deep Losses

The very small revenue base shows that commercialization has not yet translated into meaningful financial scale. Losses substantially exceeding revenue indicate that operating costs remain far above current business activity, making a durable path to profitability dependent on major growth.

Persistent Cash Burn

Sustained negative operating and free cash flow means the company is not funding operations internally. Continued deterioration in free cash flow can consume available resources, increase dependence on external capital, and constrain investment unless revenue conversion improves materially.

Reliance On Equity Funding

The sharp increase in equity alongside ongoing losses and cash burn suggests that external equity funding has been important to sustaining operations. Continued reliance on this source could dilute existing holders and leave future development dependent on access to additional capital.

Artrya Limited News

AYA FAQ

What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$2.00 and its highest was AU$6.49 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$453.27M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 119 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Aug 19, 2026. The company reported -AU$0.089 earnings per share for the quarter, missing the consensus estimate of -AU$0.055 by -AU$0.034.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.08.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 163,633,620 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.089 in its last earnings report, missing expectations of -AU$0.055. Following the earnings report the stock price went down -1.274%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology